Last reviewed · How we verify
NCT05697588
Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)
trial in Biomarkers in 900 participants. Currently enrolling.
28 February 2028
Quick facts
| Lead sponsor | Cuibai Wei，Clinical Professor |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 900 |
| Start date | 28 February 2023 |
| Primary completion | 28 February 2028 |
| Estimated completion | 28 February 2028 |
| Sites | 1 location across China |
Conditions studied
- Biomarkers — all drugs for Biomarkers →
- MCI Conversion to Dementia — all drugs for MCI Conversion to Dementia →
Sponsor
Cuibai Wei，Clinical Professor
Who can join
Adults 50 to 85, any sex, with Biomarkers or MCI Conversion to Dementia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05697588
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Biomarkers
Currently open trials in the same condition.
- NCT07012759 — Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients · recruiting
- NCT06717243 — Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) · recruiting
- NCT06924372 — Application of Salivary Biomarkers in Risk Assessment for Oral Diseases in Children With Type 1 Diabetes · active not recruiting
- NCT07345286 — Clinical Aspects, Management and Surveillance of Febrile Illnesses in DRC · recruiting
- NCT06751251 — The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determi · active not recruiting
Other Cuibai Wei，Clinical Professor trials
Trials by the same sponsor.
- NCT06871839 — The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease · recruiting
- NCT06419101 — Exploring the Diagnostic Biomarkers of Cognitive Disorders in China · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05697588 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cuibai Wei，Clinical Professor
- Last refreshed: 24 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05697588.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing